A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development Karthik VenkatakrishnanMichael D. PickardLisa L. von Moltke Current Opinion 30 September 2012 Pages: 703 - 727
Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab Bing-Bing YangPeggy LumJuan José Pérez Ruixo Review Article 30 September 2012 Pages: 729 - 740
Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza Nicolas WidmerPascal MeylanThierry Buclin Review Article 30 September 2012 Pages: 741 - 765
Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α Mario FurlanutGiorgio SoardoLoretta Franceschi Original Research Article 30 September 2012 Pages: 767 - 772
Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease Maurizio GallieniAlma MartiniMaria Fusaro Correspondence 30 September 2012 Pages: 773 - 774